Molecular testing for inherited diseases

American Journal of Clinical Pathology

Volumn 112, Issue 1 SUPPL. 1, 1999, Pages

  Vnencak Jones, Cindy L ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; DNA; HLA ANTIGEN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CYSTIC FIBROSIS; DUCHENNE MUSCULAR DYSTROPHY; FRAGILE X SYNDROME; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GENETIC DISORDER; GENETIC LINKAGE; HAPPY PUPPET SYNDROME; HEMOCHROMATOSIS; HEMOPHILIA A; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUNTINGTON CHOREA; MOLECULAR GENETICS; PATIENT REFERRAL; POINT MUTATION; PRADER WILLI SYNDROME; PRIORITY JOURNAL; REVIEW; SPINOCEREBELLAR DEGENERATION; TRINUCLEOTIDE REPEAT; UNIPARENTAL DISOMY;

CHROMOSOME MAPPING; DATABASES, FACTUAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DELETION; GENETIC DISEASES, INBORN; GENETIC SCREENING; GENETIC TECHNIQUES; GENOME, HUMAN; HUMANS; LINKAGE (GENETICS); MALE; PEDIGREE; POINT MUTATION;

EID: 0033493421     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Chang JC, Kan YW. A sensitive new prenatal test for sickle-cell anemia. N Engl J Med. 1982;307:30-32.
2. Orkin SH, Little PF, Kazazian HH, et al. Improved detection of the sickle mutation by DNA analysis. N Engl J Med. 1982;307:32-36.
3. Vnencak-Jones CL, Phillips JA. Molecular genetics and prenatal diagnosis. In: Milunsky A, ed. Genetic Disorders of the Fetus: Diagnosis, Prevention, and Treatment. Baltimore, Md: Johns Hopkins University Press; 1998:332-393.
4. van Steensel MAM, Winter RM. Internet databases for clinical geneticists: an overview. Clin Genet. 1998;54:33-40.
5. Collins FS, Patrinos A, Jordan E, et al. New goals for the US Human Genome Project: 1998-2003. Science. 1998;282:682-689.
6. Nussbaum RL, Ledbetter DH. The fragile X syndrome. In: Scriver CR, Beaudet AC, Slyy WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th Ed. New York, NY: McGraw-Hill; 1995:795-810.
7. Sutherland GR. Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium. Science. 1977;197:265-267.
8. Verkerk AJMH, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65:905-914.
9. Eberhart DE, Malter HE, Feng Y, et al. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet. 1996;5:1083-1091.
10. Oberle I, Rousseau F, Heitz D, et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science. 1991;252:1097-1102.
11. Rousseau F, Heitz D, Biancalana V, et al. Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. N Engl J Med. 1991;325:1673-1681.
12. Pieretti M, Zhang F, Fu YH, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66:817-822.
13. Sutcliffe JS, Nelson DL, Zhang F, et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet. 1992;1:397-400.
14. Sherman SL, Morton NE, Jacobs PA, et al. The marker (X) chromosome: a cytogenetic and genetic analysis. Ann Hum Genet. 1984;48:21-37.
15. Fu YH, Kuhl DPA, Pizzuti A, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell. 1991;67:1047-1058.
16. Heitz D, Devys D, Imbert G, et al. Inheritance of the fragile X syndrome: size of the fragile X premutation is a major determinant of the transition to full mutation. J Med Genet. 1992;29:794-801.
17. Eichler EE, Holden JJA, Popovich BW, et al. Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet. 1994;8:88-94.
18. Kunst CB, Leeflang EP, Iber JC, et al. The effect of FMR1 CGG repeat in interruption on mutation frequency as measured by sperm typing. J. Med Genet. 1997;34:627-631.
19. Richards RI, Sutherland GR. Simple repeat DNA is not replicated simply. Nat Genet. 1994;6:114-116.
20. Hecimovic S, Barisic I, Muller A, et al. Expand long PCR for fragile X mutation detection. Clil Genet. 1997;52:147-154.
21. Hammond LS, Macias MM, Tarleton JC, et al. Fragile X syndrome and deletions in FMR1: new case and review of the literature. Am J Med Genet. 1997;72:430-434.
22. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971-983.
23. Hackam AS, Wellington CL, Hayden MR. The fatal attraction of polyglutamine-containing proteins. Clin Genet. 1998;54:23-32.
24. Nasir J, Floresco SB, O'Kusky JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995;81:811-823.
25. Duyao MP, Auetbach AB, Ryan A, et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science. 1995;269:407-410.
26. Rubinsztein DC, Leggo J, Coles R, et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet. 1996;59:16-22.
27. Kremer B, Almquist E, Theilmann J, et al. Sex-dependent mechanisms for contractions of the CAG repeat on affected Huntington disease chromosomes. Am J Hum Genet. 1996;57:343-350.
28. International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea: Guidelines for the molecular genetics predictive test in Huntington's disease. J Med Genet. 1994;31:555-559.
29. Orr HT, Chung MY, Banfi S, et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1993;4:221-226.
30. Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet. 1994;8:221-227.
31. Zhuchenko O, Bailey J, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel. Nat Genet. 1997;15:62-69.
32. Imbert G, Saudou F, Yvert G, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet. 1996;14:285-291.
33. David G, Abbas N, Stevanin G, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet. 1997;17:65-70.
34. Gunaratne PH, Richards CS. Estimate contribution of known ataxia genes in ataxia patients undergoing DNA testing. Genet Testing. 1997/98;1:275-278.
35. Rommens JM, Iannuzzi MC, Kerem BS, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245:1059-1065.
36. Riordan JR, Rommens JM, Kerem BS, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066-1073.
37. Kerem BS, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073-1080.
38. Bear CE, Li C, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell. 1992;68:809-818.
39. Anderson MP, Berger HA, Rich DP, et al. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell. 1991;67:775-784.
40. Snouwaert JN, Brigman KK, Latour AM, et al. An animal model for cystic fibrosis made by gene targeting. Science. 1992;257:1083-1088.
41. Ratcliff R, Evans MJ, Cuthbert AW, et al. Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat Genet. 1992;4:35-41.
42. Clarke LL, Grubb BR, Gabriel SE. et al. Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis. Science. 1992;257:1125-1128.
43. Kerem E, Corey M, Kerem BS, et al. The relationship between genotype and phenotype in cystic fibrosis: analysis of the most common mutation (DF508). N Engl J Med. 1990;323:1517-1522.
44. Rozmahel R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet. 1996;12:280-287.
45. Tsui LC. Cystic fibrosis mutation data base. Toronto, Ont, Canada: The Hospital for Sick Children Web site. Available at: www.genet.sickkids.on.ca. Accessed December1998.
46. The Cystic Fibrosis Genetic Analysis Consortium. Population variation of common cystic fibrosis mutations. Hum Mutat. 1994;4:167-177.
47. Kulczycki LL, Schauf V. Cystic fibrosis in blacks in Washington DC. Am J Dis Child. 1974;127:64-67.
48. Grebe TA, Seltzer WK, DeMarchi J, et al. Genetic analysis of Hispanic individuals with cystic fibrosis. Am J Hum Genet. 1994;54:443-446.
49. Abeliovich D, Lavon IP, Lerer I, et al. Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. Am J Hum Genet. 1992;51:951-956.
50. Macek M, Mackova A, Hamosh A, et al. Identification of common cystic fibrosis mutations in African-Americans with cystic fibrosis increases the detection rate to 75%. Am J Hum Genet. 1997;60:1122-1127.
51. Shoshani T, Augarten A, Gazit E, et al. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patient in Israel, with presentation of severe disease. Am J Hum Genet. 1992;50:222-228.
52. Shuber AP, Michalowsky LA, Nass GS, et al. High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes. Hum Molec Genet. 1997;6:337-347.
53. Parad RB. Buccal cell DNA mutation analysis for diagnosis of cystic fibrosis in newborns and infants inaccessible to sweat chloride measurement. Pediatrics. 1998;101:851-855.
54. Richards B, Skoletsky J, Shuber AP, et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Molec Genet. 1993;2:159-163.
55. Middleton PG, Alton EWFW. Gene therapy for cystic fibrosis: which postman, which box? Thorax. 1998;53:197-199.
56. Caskey CT, Kaback MM, Beaudet AL. The American Society of Human Genetics statement on cystic fibrosis screening. Am J Hum Genet. 1990;46:398.
57. Wilfond BS, Fost N. The cystic fibrosis gene: medical and social implications for heterozygote detection. JAMA. 1990;263:2777-2784.
58. Beisecker L, Bowles-Beisecker B, Collins F, et al. General population screening for cystic fibrosis is premature. Am J Hum Genet. 1992;50:438-439.
59. Clayton EW, Hannig VL, Pfotenhauer JP, et al. Lack of interest by nonpregnant couples found in population-based cytstic fibrosis carrier screening. Am J Hum Genet. 1996;58:617-627.
60. Loader S, Caldwell O, Kozyra A, et al. Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet. 1996;59:234-247.
61. Witt DR, Schaefer C, Hallam P, et al. Cystic fibrosis heterozygote screening in 5,161 pregnant women. Am J Hum Genet. 1996;58:823-835.
62. NIH Consensus Statement [pamphlet]. Genetic testing for cystic fibrosis. 1997;15(4).
63. Rowley PT, Loader S, Kaplan RM. Prenatal screening for cystic fibrosis carriers: Can we afford it? Am J Hum Genet. 1998;63:A13.
64. Kuller J, Baughman R, Biolsi C. Cystic fibrosis and the NIH consensus statement: Are obstetrician-gynecologists ready to comply? Am J Hum Genet. 1998;63:A202.
65. Doksum T, Bernhardt BA, Holtzman NA. The impact of professional society statements on screening for cystic fibrosis (CF): a survey of Maryland obstetricians before and after the 1997 NIH Consensus Conference on CF. Am J Hum Genet. 1998;63:A230.
66. Merryweather-Clarke AT, Rointon JJ, Shearman JD, et al. Global revalence of putative haemochromatosis mutations. J Med. Genet. 1997;34:275-278.
67. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408.
68. Jouanolle AM, Gandon G, Jezequel P, et al. Haemochromatosis and HLA-H. Nat Genet. 1996;14:251-252.
69. Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H. Nat Genet 1996;14:249-251.
70. Feder JN, Tsuchihashi Z, Irrinki A, et al. The hemochromatosis founder mutation in HLA-H disrupts β2-microglobulin interaction and cell surface expression. J Biol Chem. 1997;272:14025-14028.
71. Lebron JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998;93:111-123.
72. Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A. 1998;95:1472-1477.
73. Zhou XY, Tomatsu S, Fleming RE, et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci USA. 1998;95:2492-2497.
74. Beutler E. The significance of the 187G (H63D) mutation in hemochromatosis. Am J Hum Genet. 1997;61:762-764.
75. Adams PC, Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology. 1998;114:319-323.
76. Shaheen NJ, Bacon BR, Grimm IS. Clinical characteristics of hereditary hemochromatosis patients who lack the C282Y mutation. Hepatology. 1998;28:526-529.
77. Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA. 1998;280:172-178.
78. Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50:509-517.
79. Hoffman EP, Fischbeck KH, Brown RH, et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med. 1988;318:1363-1368.
80. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989;45:498-506.
81. Chamberlain JS, Gibbs RA, Ranier JE, et al. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res. 1998;16:11141-11156.
82. Beggs AH, Koenig M, Boyce FM, et al. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet. 1990;86:45-48.
83. Tuffery S, Moine P, Demaille J, et al. Base substitutions in the human dystrophin gene: detection by using the single-strand conformation polymorphism (SSCP) technique. Hum Mutat. 1993;2:368-374.
84. Tuffery S, Bareil C, Demaille J, et al. Four novel dystrophin point mutations: detection by protein truncation test and transcript and analysis in lymphocytes from Duchenne muscular dystrophy patients. Eur J Hum Genet. 1996;4:143-152.
85. Ikezawa M, Minami N, Takahashi M, et al. Dystrophin gene analysis on 130 patients with Duchenne muscular dystrophy with a special reference to muscle mRNA analysis. Brain Dev. 1998;20:165-168.
86. Minetti C, Beltrame F, Marcenaro G, et al. Dystrophin at the plasma membrane from human muscle fibers shows a costameric localization. Neuromusc Disord. 1992;2:99-109.
87. Bakker E, Veenema H, Den Dunnen JT. et al. Germinal mosaicism increases the recurrence risk for "new" Duchenne muscular dystrophy mutations. J Med Genet. 1989;26:553-559.
88. Cassidy SB, Schwartz S. Prader-Willi and Angelman syndromes: disorders of genomic imprinting. Medicine. 1998;77:140-151.
89. Robinson WP, Dutly F, Nicholls RD, et al. The mechanisms involved in formation of deletions and duplications of 15q11-q13. J Med Genet. 1998;35:130-136.
90. Nicholls RD, Knoll JHM, Butler MG, et al. Genetic imprinting suggested by maternal heterodisomy in non-deletion Prader-Willi syndrome. Nature. 1989;342:281-285.
91. Tycko B. DNA methylation in genomic imprinting. Mutat Res. 1997;386:131-140
92. Constancia M, Pickard B, Kelsey G, et al. Imprinting mechanisms. Genome Res. 1998;8:881-900.
93. Sutcliffe JS, Jiang YH, Galjarrd RJ, et al. The E6-AP ubiquitin-protein ligase (UBE3A) gene is localised within a narrowed Angelman syndrome critical region. Genome Res. 1997;7:368-377.
94. Rougeulle C, Glatt H, Lalande M. The Angelman syndrome candidate gene, UBE3A/E6-AP, is imprinted in brain. Nat Genet. 1997;17:14-15.
95. Vu TH, Hoffman AR. Imprinting of the Angelman syndrome gene, UBE3A, is restricted to brain. Nat Genet. 1997;17:12-13.
96. Kishino T, Lalande M, Wagstaff J. UBE3A/E6AP mutations cause Angelman syndrome. Nat Genet. 1997;15:70-73.
97. Matsuura T, Sutcliffe JS, Fang P, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet. 1997;15:74-77.
98. Reed ML, Leff SE. Maternal imprinting of human SNRPN, a gene deleted in Prader-Willi syndrome. Nat Genet. 1994;6:163-167.
99. Mascari MJ, Gottlieb W, Rogan PK, et al. The frequency of uniparental disomy in Prader-Willi syndrome. N Engl J Med. 1992;326:1599-1607.
100. Buiting K, Saitoh S, Gross S, et al. Inherited microdeletions in the Angelman and Prader-Willi syndromes define an imprinting centre on human chromosome 15. Nat Genet. 1995;9:395-400.
101. Saitoh S, Buiting K, Cassidy SB, et al. Clinical spectrum and molecular diagnosis of Angelman and Prader-Willi syndrome patients with an imprinting mutation. Am J Med Genet. 1997;68:195-206.
102. Yang T, Adamson TE, Resnick JL, et al. A mouse model for Prader-Willi syndrome imprinting-centre mutations. Nat Genet. 1998;19:25-31.
103. Stalker HJ, Williams CA. Genetic counseling in Angelman syndrome: the challenges of multiple causes. Am J Med Genet. 1998;77:54-59.
104. Kubota T, Das S, Christian SL, et al. Methylation-specific PCR simplifies imprinting analysis. Nat Genet. 1997;16:16-17.
105. Kosaki K, McGinniss MJ, Veraksa AN, et al. Prader-Willi and Angelman syndromes: diagnosis with a bisulfite-treated methylation-specific PCR method. Am J Med Genet. 1997;73:308-313.
106. Lupski JR, Montes de Oca-Luna R, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991;66:219-232.
107. Kiyosawa H, Chance PF. Analysis of the CMT1A-REP repeat: mapping crossover breakpoints in CMT1A and HNPP. Hum Molec Genet. 1995;4:2327-2334.
108. Pentao L, Wise CA, Chinault AC, et al. Charcot-Marie-Tooth type 1A duplication appears to arise from recombination at repeat sequences flanking the 1.5 Mb monomer unit. Nat Genet. 1992;2:292-300.
109. Patel PI, Roa BB, Welcher AA, et al. The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A. Cell. 1993;72:143-151.
110. Chance PF, Bird TD, Matsumami N, et al. Trisomy 17p associated with Charcot-Marie-Tooth type 1A phenotype: evidence for gene dosage as a mechanism in CMT1A. Neurology. 1992;42:2295-2299.
111. Magyar JP, Martini R, Ruelicke T, et al. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 dosage. J. Neurosci. 1996;16:5351-5360.
112. LeGuem E, Goiuder R, Mabin D, et al. Patients homozygous for the 17p11.2 duplication in Charcot-Marie-tooth type 1A disease. Ann Neuro. 1997;47:104-108.
113. Valentijn LJ, Bass F, Wolterman RA, et al. Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A. Nat Genet. 1992;2:288-291.
114. D'Urso D, Prior R, Greiner-Petter R, et al. Overloaded endoplasmic reticulum-Golgi compartments, as a possible pathomechanism of peripheral neuropathies caused by mutations of the peripheral myelin protein PMP22. J Neurosci. 1998;18:731-740.
115. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984;312:326-330.
116. Antonarakis SE, Kazazian HH, Tuddenham EGD. Molecular etiology of factor VIII deficiency in hemophilia A. Hum Mutat. 1995;5:1-22.
117. Lakich D, Kazazian HH, Antonarakis SE, et al. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet. 1993;5:236-241.
118. Rossiter JP, Young M, Kimberland ML, et al. Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. Hum Molec Genet. 1994;3:1035-1039.
119. Liu Q, Nozari G, Sommer SS. Single-tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia A. Blood. 1998;92:1458-1459.
120. Vnencak-Jones CL, Phillips JA, Janco RL, et al. Analysis of factor VIII gene inversion mutations in 166 unrelated haemophilia A families: frequency and utility in genetic counselling. Haemophilia. 1996;2:18-23.
121. Vianello F, Radossi P, Tison T, et al. Prevalence of anti-FVIII antibodies in severe haemophilia A patients with inversion of intron 22. Br J Haematol. 1997;97:807-809.